[go: up one dir, main page]

DK3268390T3 - Fremgangsmåder til oprensning af bispecifikke antistoffer - Google Patents

Fremgangsmåder til oprensning af bispecifikke antistoffer Download PDF

Info

Publication number
DK3268390T3
DK3268390T3 DK16709808.6T DK16709808T DK3268390T3 DK 3268390 T3 DK3268390 T3 DK 3268390T3 DK 16709808 T DK16709808 T DK 16709808T DK 3268390 T3 DK3268390 T3 DK 3268390T3
Authority
DK
Denmark
Prior art keywords
purification
methods
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
DK16709808.6T
Other languages
English (en)
Inventor
Nicolas Fouque
Keith Wilson
Judith Vajda
Egbert Müller
Romain Dabre
Jean François Depoisier
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Application granted granted Critical
Publication of DK3268390T3 publication Critical patent/DK3268390T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16709808.6T 2015-03-13 2016-03-14 Fremgangsmåder til oprensning af bispecifikke antistoffer DK3268390T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132782P 2015-03-13 2015-03-13
PCT/EP2016/055474 WO2016146594A1 (en) 2015-03-13 2016-03-14 Methods of purifying bispecific antibodies

Publications (1)

Publication Number Publication Date
DK3268390T3 true DK3268390T3 (da) 2025-01-20

Family

ID=55527587

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16709808.6T DK3268390T3 (da) 2015-03-13 2016-03-14 Fremgangsmåder til oprensning af bispecifikke antistoffer

Country Status (10)

Country Link
US (2) US10457749B2 (da)
EP (1) EP3268390B1 (da)
JP (2) JP6894843B2 (da)
CN (2) CN107922476A (da)
AU (2) AU2016232349B2 (da)
CA (1) CA2979486A1 (da)
DK (1) DK3268390T3 (da)
ES (1) ES3006358T3 (da)
PT (1) PT3268390T (da)
WO (1) WO2016146594A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018159615A1 (en) * 2017-02-28 2018-09-07 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN111201238B (zh) * 2017-07-21 2023-09-08 诺夫免疫股份有限公司 产生多特异性抗体混合物及其使用方法
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CN115318256A (zh) 2018-03-08 2022-11-11 生物辐射实验室股份有限公司 阴离子交换-疏水混合模式色谱树脂
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2020136564A1 (en) 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN110272496A (zh) * 2019-06-18 2019-09-24 上海药明生物技术有限公司 利用磁珠纯化提高双特异性抗体的纯度的方法
US11896969B2 (en) 2019-09-05 2024-02-13 Bio-Rad Laboratories, Inc. Anionic exchange-hydrophobic mixed mode chromatography resins
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021170060A1 (en) * 2020-02-28 2021-09-02 Wuxi Biologics (Shanghai) Co., Ltd. Purification of bispeciifc antibodies
CA3180321A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
KR20220014531A (ko) 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
EP4204450A4 (en) 2020-08-26 2024-11-13 Marengo Therapeutics, Inc. MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
CN116917316A (zh) 2020-08-26 2023-10-20 马伦戈治疗公司 与NKp30结合的抗体分子及其用途
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
CA3258255A1 (en) * 2022-06-08 2023-12-14 Sanofi MULTI-SPECIFIC ANTIBODY PURIFICATION PROCESSES
CN116789842A (zh) * 2023-08-09 2023-09-22 康日百奥生物科技(苏州)有限公司 双特异性抗体疏水层析纯化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06211897A (ja) * 1993-01-19 1994-08-02 Tosoh Corp 免疫グロブリンの精製方法
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013504B1 (ru) * 2005-04-11 2010-06-30 Медарекс, Инк. Способ очистки белков
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
WO2008119353A1 (en) * 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2419436A1 (en) * 2009-04-13 2012-02-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
EP2513312B1 (en) 2009-12-17 2015-03-18 NovImmune SA Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
JP5997154B2 (ja) * 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
KR102492792B1 (ko) * 2011-10-11 2023-01-30 제넨테크, 인크. 이중특이적 항체의 개선된 어셈블리
US10047144B2 (en) * 2011-10-19 2018-08-14 Novimmune Sa Methods of purifying antibodies
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1223108A1 (zh) * 2013-08-19 2017-07-21 F. Hoffmann-La Roche Ag 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物

Also Published As

Publication number Publication date
JP6894843B2 (ja) 2021-06-30
PT3268390T (pt) 2025-01-13
AU2022202563A1 (en) 2022-05-12
AU2016232349A1 (en) 2017-10-05
US20200181287A1 (en) 2020-06-11
CN107922476A (zh) 2018-04-17
CN114249831A (zh) 2022-03-29
CA2979486A1 (en) 2016-09-22
JP2018510868A (ja) 2018-04-19
EP3268390A1 (en) 2018-01-17
WO2016146594A1 (en) 2016-09-22
US10457749B2 (en) 2019-10-29
ES3006358T3 (en) 2025-03-18
AU2016232349B2 (en) 2022-01-20
EP3268390B1 (en) 2024-10-30
JP2021130714A (ja) 2021-09-09
US20160264685A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
DK3268390T3 (da) Fremgangsmåder til oprensning af bispecifikke antistoffer
IL263690A (en) Purification of multispecific antibodies
DK3172221T3 (da) Oprensningsplatform til bispecifikke antistoffer
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
DK3301115T3 (da) Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3313876T3 (da) Multispecifikke antigenbindende proteiner
DK3699198T3 (da) Fremgangsmåder til tumorbehandling ved hjælp af bispecifikke CD3XCD20-antistoffer
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3510042T3 (da) Fremgangsmåde til rensning af antistoffer
DK3608337T3 (da) Bispecifikke T-celleaktiverende antigenbindende molekyler
DK3116891T3 (da) Immunglobulinrensning ved hjælp af forrensningstrin
DK3160994T3 (da) Multispecifikke antigenbindende proteiner
EP3182987C0 (en) HUMANIZED ANTI-TAU ANTIBODIES
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3113858T3 (da) Fremgangsmåde til oprensning af il-15/il-15ralpha-baserede konjugater
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
HUE061076T2 (hu) Humanizált anti-C1s ellenanyagok alkalmazási eljárások
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3287523T3 (da) Fremgangsmåde til sekretorisk fremstilling af protein
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3665173T3 (da) Ny fremgangsmåde til yntetisering af amanitiner
DK3201346T3 (da) Fremgangsmåder til fremstilling af biopolymer-matrix kompositmaterialer